Overview

Study to Assess PDM608 in Healthy Adult Subjects

Status:
COMPLETED
Trial end date:
2024-04-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Calibr, a division of Scripps Research
Collaborators:
Alzheimer's Drug Discovery Foundation
Michael J. Fox Foundation for Parkinson's Research